Biotech | March 29, 2022
Dupixent is a star in Sanofi’s immunology strategy
Dupixent peak sales ambition raised to more than €13 billion
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
John Shaw, who is a Glasgow University graduate, along with his wife Kiran Mazumdar-Shaw had gifted US $ 7.5 million to the university in July 2019
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
Subscribe To Our Newsletter & Stay Updated
